Researchers at the University of California, Davis have developed H2CBD, a fully synthetic analog of CBD designed to treat seizures without the psychoactive effects associated with Cannabis.

In collaboration with MIT, Researchers at the University of California, Davis have contributed to the development of an Integrated Opitcal Sampling Platform.

Researchers at the University of California, Davis have developed an approach to combat Feline Infectious Peritonitis (FIP) through an in vitro-transcribed (IVT) RNA vaccine targeting the FCoV nucleocapsid (N) protein antigen.

Please view this family of technologies HERE

Researchers at the University of California, Davis, have developed a monoclonal antibody for treating and diagnosing T cell lymphoma in dogs as well as monoclonal antibodies targeting c-KIT for treating and diagnosing mast cell tumors in dogs.

Researchers at the University of California, Davis have developed monoclonal antibodies engineered for the treatment and detection of autoimmune disorders and cancers in dogs.

Researchers at the University of California, Davis have developed a technology that introduces an alternative topology for Fibonacci switched-capacitor converters that significantly reduces switch losses and improves efficiency.

In PET imaging, patient motion, such as respiratory and cardiac motion, are a major source of blurring and motion artifacts. Researchers at the University of California, Davis have developed a technology designed to enhance PET imaging resolution without the need for external devices by effectively mitigating these artifacts